These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24941346)

  • 1. Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells.
    Atmaca H; Uzunoglu S
    Eur Cytokine Netw; 2014 Mar; 25(1):1-7. PubMed ID: 24941346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells.
    Atmaca H; Bozkurt E; Uzunoglu S; Uslu R; Karaca B
    Toxicol Lett; 2013 Aug; 221(2):128-36. PubMed ID: 23792433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells.
    Acikgoz E; Guven U; Duzagac F; Uslu R; Kara M; Soner BC; Oktem G
    PLoS One; 2015; 10(10):e0141090. PubMed ID: 26485709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-angiogenic effect of Biophytum sensitivum is exerted through its cytokine modulation activity and inhibitory activity against VEGF mRNA expression, endothelial cell migration and capillary tube formation.
    Guruvayoorappan C; Kuttan G
    J Exp Ther Oncol; 2007; 6(3):241-50. PubMed ID: 17552364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.
    Allavena P; Signorelli M; Chieppa M; Erba E; Bianchi G; Marchesi F; Olimpio CO; Bonardi C; Garbi A; Lissoni A; de Braud F; Jimeno J; D'Incalci M
    Cancer Res; 2005 Apr; 65(7):2964-71. PubMed ID: 15805300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total alkaloids of Rubus alceifolius Poir shows anti-angiogenic activity in vivo and in vitro.
    Zhao J; Lin W; Zhuang Q; Zhong X; Cao Z; Hong Z; Peng J
    Integr Cancer Ther; 2014 Nov; 13(6):520-8. PubMed ID: 25148840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
    Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
    Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of endothelial cell differentiation and proinflammatory cytokine production during angiogenesis by allyl isothiocyanate and phenyl isothiocyanate.
    Thejass P; Kuttan G
    Integr Cancer Ther; 2007 Dec; 6(4):389-99. PubMed ID: 18048887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
    Dossi R; Frapolli R; Di Giandomenico S; Paracchini L; Bozzi F; Brich S; Castiglioni V; Borsotti P; Belotti D; Uboldi S; Sanfilippo R; Erba E; Giavazzi R; Marchini S; Pilotti S; D'Incalci M; Taraboletti G
    Int J Cancer; 2015 Feb; 136(3):721-9. PubMed ID: 24917554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
    Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
    Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
    Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
    Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-angiogenic effects of Qingdu granule on breast cancer through inhibiting NFAT signaling pathway.
    Zhao X; Liu J; Feng L; Ge S; Yang S; Chen C; Li X; Peng L; Mu Y; Wang Y; Gu D; Guo Y; Lin G; Deng B; Cheng Z; Cai D
    J Ethnopharmacol; 2018 Aug; 222():261-269. PubMed ID: 29337215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K20E, an oxidative-coupling compound of methyl caffeate, exhibits anti-angiogenic activities through down-regulations of VEGF and VEGF receptor-2.
    Pan CH; Lin WH; Chien YC; Liu FC; Sheu MJ; Kuo YH; Wu CH
    Toxicol Appl Pharmacol; 2015 Jan; 282(2):215-26. PubMed ID: 25481497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
    Fernand VE; Losso JN; Truax RE; Villar EE; Bwambok DK; Fakayode SO; Lowry M; Warner IM
    Chem Biol Interact; 2011 Jul; 192(3):220-32. PubMed ID: 21457705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Punarnavine, an alkaloid from Boerhaavia diffusa exhibits anti-angiogenic activity via downregulation of VEGF in vitro and in vivo.
    Saraswati S; Alhaider AA; Agrawal SS
    Chem Biol Interact; 2013 Nov; 206(2):204-13. PubMed ID: 24060680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin in soft tissue sarcomas.
    Brodowicz T
    Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo.
    Zhong ZF; Hoi PM; Wu GS; Xu ZT; Tan W; Chen XP; Cui L; Wu T; Wang YT
    J Ethnopharmacol; 2012 Jun; 141(2):721-7. PubMed ID: 21911050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
    Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.